Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $119.62 to $122.78
• 50-Day Range: $87.54 to $122.96
• 52-Week Range: $84.23 to $157.98
• Volume: 1.28 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $12.14 billion
• P/E Ratio: 37.28
• Dividend Yield: N/A
• Price Target: $162.00
• Consensus Rating: Moderate Buy

Neurocrine Biosciences Stock Analysis - MarketRank™

Neurocrine Biosciences scored higher than 99% of companies evaluated by MarketBeat, and ranked 21st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neurocrine Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 51.17%

Earnings Growth

Earnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurocrine Biosciences is 37.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurocrine Biosciences is 37.28, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.

Price to Earnings Growth Ratio

Neurocrine Biosciences has a PEG Ratio of 0.77. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Neurocrine Biosciences has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.54% of the outstanding shares of Neurocrine Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neurocrine Biosciences has recently increased by 2.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurocrine Biosciences does not currently pay a dividend.

Dividend Growth

Neurocrine Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.9 / 5
• Environmental Score: -2.61

Percentage of Shares Shorted

4.54% of the outstanding shares of Neurocrine Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neurocrine Biosciences has recently increased by 2.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.47

News Sentiment

Neurocrine Biosciences has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Neurocrine Biosciences this week, compared to 16 articles on an average week.

Search Interest

6 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

5 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,306,000.00 in company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Neurocrine Biosciences is held by insiders.

Percentage Held by Institutions

92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NBIX Stock Analysis - Frequently Asked Questions

How have NBIX shares performed this year?

Neurocrine Biosciences' stock was trading at $136.50 at the start of the year. Since then, NBIX stock has decreased by 10.2% and is now trading at $122.64.
View the best growth stocks for 2025 here.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Monday, May, 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $0.62. Neurocrine Biosciences's revenue for the quarter was up 11.1% on a year-over-year basis.
Read the conference call transcript.

How will Neurocrine Biosciences' stock buyback program work?

Neurocrine Biosciences' Board of Directors initiated a stock buyback program on Friday, February 21st 2025, which allows the company to repurchase $500,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

Who are Neurocrine Biosciences' major shareholders?

Top institutional shareholders of Neurocrine Biosciences include Vanguard Group Inc. (10.05%), Dodge & Cox (5.59%), Wellington Management Group LLP (2.12%) and Price T Rowe Associates Inc. MD (1.56%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Malcolm Lloyd-Smith, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow.
View institutional ownership trends.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBIX
• CIK: 914475
• Web: www.neurocrine.com
• Phone: (858) 617-7600
• Fax: 858-617-7602
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $162.00
• High Stock Price Target: $219.00
• Low Stock Price Target: $115.00
• Potential Upside/Downside: +32.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 22 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.95
• Trailing P/E Ratio: 37.28
• Forward P/E Ratio: 28.65
• P/E Growth: 0.77
• Net Income: $341.30 million
• Net Margins: 14.49%
• Pretax Margin: 20.63%
• Return on Equity: 13.38%
• Return on Assets: 9.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.40
• Quick Ratio: 3.28

Sales & Book Value

• Annual Sales: $2.41 billion
• Price / Sales: 5.03
• Cash Flow: $3.57 per share
• Price / Cash Flow: 34.35
• Book Value: $25.97 per share
• Price / Book: 4.72

Miscellaneous

• Outstanding Shares: 98,966,000
• Free Float: 95,417,000
• Market Cap: $12.14 billion
• Optionable: Optionable
• Beta: 0.26